| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies | Company's Home Page |
| Xenogen, Inc. |
| 860 Atlantic Avenue, Alameda, CA 94501 * (510) 291-6100 |
| Business Description | The company has developed and is manufacturing and marketing a novel system designed to improve the efficiency and productivity of drug discovery and development by facilitating biological assessment. Their in vivo biophotonic imaging system allows us to measure light emitted from inside a living animal. |
|
Filing Information Not yet | |||
| To Trade As | XGEN (NASNTL) | Industry | Service (SIC 8731) |
| Type of Stock Offered | Common Shares | Filing Date | 9/29/00 |
| Domestic Shares Filed | 0 | Filing Price | - - |
| Foreign Shares Filed | 0 | Offering Amount | $75,000,000 |
| Company Shares | 0 | Est. Expenses | - - |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| UBS Warburg LLC | Lead Manager | |
| Dain Rauscher Wessels | Co-manager | (612) 371-2818 |
| Prudential Vector Healthcare | Co-manager | (800) 546-1231 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 6 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/97 | 12/31/98 | 12/31/99 | 6/30/99 | 6/30/00 | ||
| Revenues | - | - | 0.063 | 0.084 | 1.293 | 0.257 | 0.865 |
| Income from Oper. | - | - | -0.462 | -3.306 | -7.254 | -3.271 | -5.678 |
| Net Income | - | - | -0.467 | -3.244 | -7.136 | -3.228 | -5.518 |
| E.P.S | - | - | - | - | - | - | - |
| Revenue Growth (%) | - | - | 33.33 | 1,439.286 | 236.58 | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -5.75 | -2.00 | -4.70 | ||||
| Cash Flow - Inv. | -5.67 | -5.04 | 1.95 | ||||
| Cash Flow - Fin. | 12.77 | 10.84 | 29.38 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 6/30/00 | Financial Ratios | ||||
| Total Assets | 36.14 | Current Assets | 32.74 | Current Ratio | 14.45 |
| Total Liab. | 51.58 | Current Liab. | 2.27 | Debt Ratio | 142.72% |
| Total Equity | -15.44 | Working Cap. | 30.47 | Debt to Equity Ratio | - |
| Cash | 30.38 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used to fund operations including continued development of manufacturing of existing products, research, development and commercialization of new applications for the technology, hiring of additional personnel to support growth, expansion of facilities and for other working capital and general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Wilson, Sonsini, Goodrich & Rosati |
| Bank's Law Firm | Dewey Ballantine |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Brentwood Associates VIII, L.P. | 18.20 | |
| Harvard Private Capital Holdings, Inc. | 15.80 | |
| Delphi Ventures IV, L.P. | 9.70 | |
| S.R. One, Limited | 9.40 | |
| Invemed Fund, L.P. | 6.60 | |
| Note: represents ownership of 5% or more prior to the offering. | ||